Showing results (461-470 of 630) with videos related to
Sort By:
Pageof 63
The Journal of Allergy and Clinical Immunology|August 17, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study resultsJonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2020
Real-world persistence with dupilumab among adults with atopic dermatitisJonathan I Silverberg, Emma Guttman-Yassky, Abhijit Gadkari, et al.American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.American Journal of Clinical Dermatology|February 22, 2023
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical TrialsJonathan I Silverberg, Charles W Lynde, Katrina Abuabara, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 13, 2019
Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patientsDonald Lei, Muhammad Yousaf, Sherief R Janmohamed, et al.Dermatology and Therapy|December 20, 2025
Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect ComparisonRaj Chovatiya, April Armstrong, Leon Kircik, et al.JAMA Dermatology|February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical TrialsAmy S Paller, Jonathan I Silverberg, Michael J Cork, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2024
Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2)J I Silverberg, M N Mustapa, F Reid, et al.BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.Journal of the American Academy of Dermatology|August 27, 2025
Chronic skin conditions and life trajectories: development and validation of "Dermatology Long-Term Life Impact Measure (DLLIM)"Jonathan I Silverberg, Charbel Skayem, Ann'Laure Demessant Flavigny, et al.Pageof 63